RSV Prevention Products and Severe RSV-Associated Disease Among Infants

What is the population-level impact of infant nirsevimab and respiratory syncytial virus (RSV) antenatal vaccine on the relative rate of RSV-associated hospitalizations and emergency department (ED) visits among infants in Washington state?This cohort study including 16 775 RSV-related hospitalizations estimated a statistically significant 43.0% relative decrease in the population rate of RSV-associated hospitalization and ED visits for children aged 7 months or younger associated with RSV prevention products in the second year of use (2024-2025).This study suggests that infant nirsevimab and antenatal RSV vaccine were associated with reduced burden of severe RSV disease among infants and supports continued use of these products in the state.

Corresponding Author: Julia C. Bennett, PhD, Washington State Department of Health, 1610 NE 150th St, Shoreline, WA 98155 (julia.bennett@doh.wa.gov).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.